Moxifloxacin Population Pharmacokinetics and Model-Based Comparison of Efficacy between Moxifloxacin and Ofloxacin in African Patients

Contribution of Moxifloxacin or Levofloxacin in Second-Line Regimens with or without Continuation of Pyrazinamide in Murine Tuberculosis

(2013) Zahoor Ahmad et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Rifampicin and moxifloxacin for tuberculous meningitis – Authors' reply

(2013) Rovina Ruslami et al.   LANCET INFECTIOUS DISEASES

Population Pharmacokinetics and Pharmacodynamics of Ofloxacin in South African Patients with Multidrug-Resistant Tuberculosis

(2012) Emmanuel Chigutsa et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effect of Coadministration of Moxifloxacin and Rifampin on Mycobacterium tuberculosis in a Murine Aerosol Infection Model

(2012) V. Balasubramanian et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Moxifloxacin Population Pharmacokinetics in Patients with Pulmonary Tuberculosis and the Effect of Intermittent High-Dose Rifapentine

(2012) Simbarashe P. Zvada et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis

(2012) F. A. Sirgel et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Randomized Pharmacokinetic and Pharmacodynamic Comparison of Fluoroquinolones for Tuberculous Meningitis

(2011) Guy E. Thwaites et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update

(2011) D. Falzon et al.   EUROPEAN RESPIRATORY JOURNAL

The Combination of Rifampin plus Moxifloxacin Is Synergistic for Suppression of Resistance but Antagonistic for Cell Kill of Mycobacterium tuberculosis as Determined in a Hollow-Fiber Infection Model

(2010) G. L. Drusano et al.   mBio

Handling Data Below the Limit of Quantification in Mixed Effect Models

(2009) Martin Bergstrand et al.   AAPS Journal

Surveillance of Antituberculosis Drug Resistance Among Children From the Western Cape Province of South Africa—An Upward Trend

(2009) H. Simon Schaaf et al.   AMERICAN JOURNAL OF PUBLIC HEALTH

P-Glycoprotein-Mediated Transport of Moxifloxacin in a Calu-3 Lung Epithelial Cell Model

(2009) J. Brillault et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics of Moxifloxacin in Cerebrospinal Fluid and Plasma in Patients with Tuberculous Meningitis

(2009) J. W. C. Alffenaar et al.   CLINICAL INFECTIOUS DISEASES

Selective Role of Sulfotransferase 2A1 (SULT2A1) in the N-Sulfoconjugation of Quinolone Drugs in Humans

(2009) L. Senggunprai et al.   DRUG METABOLISM AND DISPOSITION

Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial

(2009) Marcus B Conde et al.   LANCET

Repeated Administration of High-Dose Intermittent Rifapentine Reduces Rifapentine and Moxifloxacin Plasma Concentrations

(2008) K. Dooley et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Mechanism-Based Concepts of Size and Maturity in Pharmacokinetics

(2007) B.J. Anderson et al.   Annual Review of Pharmacology and Toxicology